Form 4: Gilead Sciences Director Sells Shares
Insider Transaction (Form 4)
Jeffrey Bluestone, a Director of Gilead Sciences, Inc., sold 5,000 shares of common stock on August 20, 2026.
Summary
- Option exercise/conversion: acquired 1,165 Common Stock at $67.45 ($78,579) on August 20, 2026; holds 11,231 after (Direct).
- Open-market sale: disposed of 1,165 Common Stock at $143.75 ($167,474) on August 20, 2026; holds 10,066 after (Direct).
- Option exercise/conversion: acquired 1,816 Common Stock at $67.45 ($122,489) on August 20, 2026; holds 11,882 after (Direct).
- Open-market sale: disposed of 1,816 Common Stock at $144.92 ($263,183) on August 20, 2026; holds 10,066 after (Direct).
- Option exercise/conversion: acquired 1,658 Common Stock at $67.45 ($111,832) on August 20, 2026; holds 11,724 after (Direct).
- Open-market sale: disposed of 1,658 Common Stock at $145.73 ($241,618) on August 20, 2026; holds 10,066 after (Direct).
- Option exercise/conversion: acquired 26 Common Stock at $67.45 ($1,754) on August 20, 2026; holds 10,092 after (Direct).
- Open-market sale: disposed of 26 Common Stock at $146.36 ($3,805) on August 20, 2026; holds 10,066 after (Direct).
- Option exercise/conversion: acquired 335 Common Stock at $61.35 ($20,552) on August 20, 2026; holds 10,401 after (Direct).
- Open-market sale: disposed of 335 Common Stock at $146.26 ($48,997) on August 20, 2026; holds 10,066 after (Direct).
- Option exercise/conversion: disposed of 4,665 Non-qualified Stock Option (Right to Buy) on August 20, 2026 (Direct).
- Option exercise/conversion: disposed of 335 Non-qualified Stock Option (Right to Buy) on August 20, 2026; holds 11,395 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $725,078 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jeffrey Bluestone — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-20 | Option exercise/conversion | Common Stock | 1,165 | $67 | $78.6K | 11,231 |
| 2026-08-20 | Open-market sale | Common Stock | 1,165 | $144 | $167.5K | 10,066 |
| 2026-08-20 | Option exercise/conversion | Common Stock | 1,816 | $67 | $122.5K | 11,882 |
| 2026-08-20 | Open-market sale | Common Stock | 1,816 | $145 | $263.2K | 10,066 |
| 2026-08-20 | Option exercise/conversion | Common Stock | 1,658 | $67 | $111.8K | 11,724 |
| 2026-08-20 | Open-market sale | Common Stock | 1,658 | $146 | $241.6K | 10,066 |
| 2026-08-20 | Option exercise/conversion | Common Stock | 26 | $67 | $1.8K | 10,092 |
| 2026-08-20 | Open-market sale | Common Stock | 26 | $146 | $3.8K | 10,066 |
| 2026-08-20 | Option exercise/conversion | Common Stock | 335 | $61 | $20.6K | 10,401 |
| 2026-08-20 | Open-market sale | Common Stock | 335 | $146 | $49.0K | 10,066 |
| 2026-08-20 | Option exercise/conversion | Non-qualified Stock Option (Right to Buy) | 4,665 | — | — | 0 |
| 2026-08-20 | Option exercise/conversion | Non-qualified Stock Option (Right to Buy) | 335 | — | — | 11,395 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-20 | Option exercise/conversion (1,165 shares) |
| 2026-08-20 | Open-market sale (1,165 shares) |
| 2026-08-20 | Option exercise/conversion (1,816 shares) |
| 2026-08-20 | Open-market sale (1,816 shares) |
| 2026-08-20 | Option exercise/conversion (1,658 shares) |
| 2026-08-20 | Open-market sale (1,658 shares) |
| 2026-08-20 | Option exercise/conversion (26 shares) |
| 2026-08-20 | Open-market sale (26 shares) |
| 2026-08-20 | Option exercise/conversion (335 shares) |
| 2026-08-20 | Open-market sale (335 shares) |
| 2026-08-20 | Option exercise/conversion (4,665 shares) |
| 2026-08-20 | Option exercise/conversion (335 shares) |
Keywords
insider transaction, Form 4, GILD, GILEAD SCIENCES, INC., bearish, Jeffrey Bluestone
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.